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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
(a) To determine the effectiveness of radiotherapy in localised Ewing’s sarcoma in children for event-free survival and overall survival
when compared to children undergoing surgery only.
(b) To determine the role of radiotherapy for Ewing’s sarcoma on risk of growth arrest and second malignancies
B A C K G R O U N D
Description of the condition
Ewing’s sarcoma family tumours (EWS), which include classic Ew-
ing’s sarcoma in addition to primitive neuroectodermal tumour
and Askin tumour, are the second most common variety of pri-
mary bone cancer in adolescents and young adults (Subbiah 2009).
Annual incidence of Ewing’s sarcoma is low (0.6 per million) be-
fore age five but rises in concordance with the arrival of puberty to
approach a peak rate of 5 per million, accounting for 3% of pae-
diatric cancers. Most common sites of tumour are pelvis, femur,
tibia and chest wall (Ludwig 2008).
The single most important criterion considered when planning
treatment of people with Ewing’s sarcoma is the presence or ab-
sence of metastatic disease (Ludwig 2008). The treatment algo-
rithm for localised disease consists generically of three stages: ini-
tial cytoreduction to eradicate micrometastatic disease and facili-
tate effective local control measures with wide negative margins;
definitive radiation or surgical therapy to eradicate all known dis-
ease; and consolidation with adjuvant chemotherapy to reduce the
likelihood of tumour recurrence. This multi-disciplinary care in-
corporating advances in diagnosis, surgery, chemotherapy, and ra-
diation has substantially improved the survival rate of people with
localised Ewing’s sarcoma to nearly 70% (Subbiah 2009).
Description of the intervention
Known to be radiation-sensitive since the earliest clinical re-
ports, localised Ewing’s sarcoma had been treated throughoutmost
of the 20th century primarily with radiation (Indelicato 2008a;
Indelicato 2008b; Laskar 2008). Today, this modality is used less
frequently as a definitive measure, given the potential morbidities
of this approach (secondary malignancies and adverse effects on
bone growth) in children (Ludwig 2008). Contemporary surgical
advances, that preserve limb function even after excision with a
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wide margin, provide a higher survival rate and reduce the need
for adjuvant radiation (Ludwig 2008). However, there is ongoing
debate as to whether surgery and radiotherapy are comparable for
local control. Though there are no randomised controlled studies
that directly compare surgery to radiation for definitive local con-
trol, at least four studies report local failure rates nearly three-fold
higher in participants treated with radiation alone (30% failure)
compared to surgery alone (10% or less) (Bacci 2004; Donaldson
1998; Krasin 2004; Schuck 2003). These results should be inter-
preted with caution as they are retrospective studies susceptible
to inherent bias in the selection of one therapy over another. The
choice of local therapy is influenced by multiple clinical character-
istics such as age, tumour location, size, surgical margins, response
to chemotherapy, availability of surgical or radiotherapy resources,
anticipated morbidity and patient preference. People referred for
surgery have tumours which are usually small, peripheral in loca-
tion, and follow a good response to induction chemotherapy. Tu-
mours requiring radiotherapy are often large, central in location,
and follow a poor response to induction chemotherapy (Ludwig
2008).
Several radiotherapy parameters have been studied, including
treatment volume, timing, and dose. For dose, there have been
conflicting results regarding its impact on local control. St Jude
Children’s Research Hospital (SJCRH) reported local control of
58% following 30 to 60 Gy (Arai 1991). The SJCRH investiga-
tors used lower doses of 30 to 36 Gy, for those who responded
to chemotherapy, but 50 to 60 Gy for those with no response
or progressive disease during chemotherapy. Improved outcome
among chemotherapy responders was recorded. They also showed
local tumour control is related to the size of the primary tumour.
Those with a tumour of less than 8 cm in diameter who received
a median radiation dose of 35 Gy had 90% local control, while
for those with a tumour of 8 cm or more, local control dropped
to 52% (Arai 1991). On the other hand, the Intergroup Ewing
Sarcoma Study (IESS) showed no dose response between 30 and
65 Gy; local control was achieved in 6/6 (100%) with 30 to 39.9
Gy, 37/43 (86%) with 40 to 49.9 Gy, 80/91 (88%) with 50 to
59.9 Gy and 50/53 (94%) with 60 Gy or more (Razek 1980).
Similarly, a recent paper from Memorial Sloan Kettering Cancer
Center did not show a radiotherapy dose response (La 2006).
There are concerns about potential late effects and second ma-
lignancies in long-term survivors. People treated for Ewing’s sar-
coma have a significantly higher risk of developing subsequent
neoplasms than the general population.Treatment-related acute
myeloid leukaemia (AML) and myelodysplastic syndrome (MDS)
have generally been reported to occur in 1% to 2% of survivors
of Ewing’s sarcoma (Fuchs 2003; Goldsby 2008), although some
dose-intensive regimens appear to be associated with a higher risk
of haematological malignancy (Bhatia 2007; Kushner 1998;Navid
2008). Treatment-related AML and MDS arise most commonly
at two to five years following diagnosis.
Survivors of Ewing’s sarcoma remain at increased risk of develop-
ing a subsequent solid tumour throughout their lifetime. Sarco-
mas usually occur within the prior radiation field (Hawkins 1996;
Kuttesch 1996). The risk of developing a sarcoma following radia-
tion therapy is dose-dependent, with higher doses associated with
an increased risk of sarcoma development (Fuchs 2003; Goldsby
2008). The cumulative incidence of subsequent neoplasms in chil-
dren treated for Ewing’s sarcoma between 1970 and 1986 at 25
years after diagnosis was 9.0% (95% confidence interval 5.8 to
12.2). Most of these people received radiation therapy; compa-
rable long-term data do not yet exist for significant numbers of
people who did not receive radiation therapy (Ginsberg 2010).
Why it is important to do this review
Current opinion favouring surgery is based on retrospective anal-
ysis and should therefore be interpreted with caution. This re-
view will provide a systematic analysis of the available evidence
for the effectiveness of radiotherapy for local control in localised
Ewing’s sarcoma compared to surgery alone, and should therefore
contribute to facilitating evidence-based treatment decisions in a
complex field.
O B J E C T I V E S
(a) To determine the effectiveness of radiotherapy in localised
Ewing’s sarcoma in children for event-free survival and overall
survival when compared to children undergoing surgery only.
(b) To determine the role of radiotherapy for Ewing’s sarcoma on
risk of growth arrest and second malignancies
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials and quasi-randomised controlled tri-
als comparing radiotherapy and surgery as part of treatment for
localised Ewing’s sarcoma in children.
Types of participants
The review will include trials on children (less than 18 years of
age) with a diagnosis of localised Ewing’s sarcoma established by
histopathology and a negative metastatic workup. There will be
no restriction by participant gender or ethnic group. We will also
consider studies which include participants younger than 18 years
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and older than 18 years. For such studies we will assess if separate
data are available for participants younger than 18 years. If data are
not given separately for our review population we will not include
these studies in the review.
Types of interventions
We will include trials which compare radiotherapy versus surgery
for localised Ewing’s sarcoma in addition to neo-adjuvant and
adjuvant chemotherapy. The type and dose of chemotherapymust
be the same in both intervention and control groups.
Types of outcome measures
Primary outcomes
Event-free survival (EFS) is defined as the time from the date of
diagnosis until the event or last participant contact, at which time
the participant is censored. An ’event’ will be defined as stated by
the authors of included studies. Overall survival is defined as the
time from the date of diagnosis until the death of the participant
from any cause.
Secondary outcomes
Risk of second malignancy, defined as cancer that develops after
treatment for a first cancer. The risk of growth retardation will be
determined in terms of limb length discrepancy.
Wewill investigate the above-mentioned outcomes, although these
outcome measures are not used as criteria for inclusion of studies.
Studies will be chosen purely on their relevance to the study ob-
jective.
Search methods for identification of studies
Wewill not impose any language or date of publication restriction.
We will update searches every two years.
Electronic searches
Wewill search the following electronic databases for primary stud-
ies: the Cochrane Central Register of Controlled Trials (CEN-
TRAL, The Cochrane Library, latest issue), MEDLINE/PubMed
(from 1945 to present), EMBASE/Ovid (from 1980 to present).
The Cochrane Childhood Cancer Group (CCG) will run the
searches in these databases.
The search strategies for the different electronic databases (using a
combination of controlled vocabulary and text words) are shown
in the appendices (Appendix 1; Appendix 2; Appendix 3).
Searching other resources
We will locate information about trials not identified in CEN-
TRAL, MEDLINE and EMBASE, either published or unpub-
lished, by searching the reference lists of relevant trial articles and
review articles.
We also plan to scan the conference proceedings of the In-
ternational Society of Paediatric Oncology (SIOP) (from 2009
to present), the European Musculo-Skeletal Oncology Society
(E.M.S.O.S.) from 2012 onwards, the International Society of
Limb Salvage (ISOLS) (2011 and 2013) and the American Society
of Clinical Oncology (ASCO; meetinglibrary.asco.org/abstracts)
(from 2009 to present).
We will search for ongoing trials by scanning the following trial
registers:
www.clinicaltrials.gov
www.who.int/ictrp/en/
We will also handsearch the journals in which the included studies
most frequently appear. We will search the top five journals (ac-
cording to the number of included studies provided) for the last
12 months.
We will contact authors of relevant papers regarding any further
published or unpublished work.
Data collection and analysis
Selection of studies
Two review authors (IQ and JD) will download all titles and ab-
stracts retrieved by electronic searching to the reference manage-
ment database Endnote, will remove duplicates and examine the
remaining references independently. These two review authors will
screen titles and abstracts of references identified from the search
and will eliminate articles that are obviously not relevant to the
search question. Wewill assess all other references in full text. Each
review author will then independently determine if these trials are
eligible for inclusion, resolving disagreements about inclusion by
discussion and if necessary by recourse to a third review author
(MU).We will contact study authors for further details when pa-
pers contain insufficient information to make a decision about el-
igibility. We will document reasons for exclusion. We will include
a flow chart/diagram of the search in the review.
Data extraction and management
Two review authors (IQ and NA, not masked to the study details)
will independently perform extraction of data from the included
trials, using a data extraction form designed and pilot-tested. We
will extract each trial component, such as study design, partic-
ipants, setting, intervention and control, co-interventions, out-
comes and results, follow-up duration, funding source details, the
declaration of interests for the primary investigators, and risk of
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bias domains, and will present them in a table of Characteristics
of Included Studies.
The review authors will compare results and resolve disagreements
by discussion until a consensus is reached. If there is no consen-
sus, a third review author (MU) will settle the discrepancies. We
will document relevant disagreements. We will write to the study
authors for any missing, incomplete or unclear data. One review
author (IQ) will enter the data in to Review Manager 5 software
(RevMan 2012) and another (JD) will check the data entered
manually. A third author (ZL) will check the whole process.
Dealing with duplicate publications
If there are multiple publications for one study, we will use the
one with the most recent data. Wemay use earlier publications for
extracting information on baseline characteristics or methodology.
Assessment of risk of bias in included studies
Two review authors (IQ and JD) will independently assess the risk
of bias for each study (that is, selection bias, performance bias,
detection bias (for each outcome separately), attrition bias (for
each outcome separately), reporting bias and other potential bias)
using the ’Risk of bias’ items as described in the module of the
Childhood Cancer Group (Module CCG), which are based on the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We will contact study authors if relevant data are missing.
We will take the risk of bias in included studies into account in
the interpretation of the review’s results.
Measures of treatment effect
Measures of treatment effect will depend on the types of data
presented in the individual studies.
1) Hazard ratios (HRs) for time-to-event variables (event-free
survival and overall survival). We will use Parmar’s method if haz-
ard ratios have not been explicitly presented in the study (Parmar
1998).
2) Risk ratios (RRs) for dichotomous variables (risk of second
malignancy and growth arrest).
Unit of analysis issues
Studies with more than two treatment groups
If we identify studies with more than two intervention groups
(multi-arm studies), we will where possible combine groups to
create a single pair-wise comparison or use the methods set out
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) to avoid double-counting study participants. For
the subgroup analyses, when the control group is shared by two
or more study arms, we will divide the control group (events and
total population) over the number of relevant subgroups to avoid
double-counting the participants.
Dealing with missing data
As stated before, when relevant data regarding study selection,
data extraction and risk of bias assessment are missing, we will
attempt to contact the study authors to retrieve the missing data.
If after 30 days we cannot obtain this information, we will use
the available information and perform an ‘available case analysis’
instead of an intention-to-treat analysis if possible. An ‘available
case analysis’ includes data on only those participants whose results
are known, using as a denominator the total number of people
who had data recorded for the particular outcome in question (the
participants are analysed according to the group towhich theywere
randomised). If we do not have enough information to include a
certain outcome in the analysis, we will declare this.
We will describe missing outcomes of the included studies by
reporting proportions of randomised participants for whom no
outcome data were obtained (with reasons) by outcome and by
randomised group. We will address the potential impact of the
missing outcomes on the results of the included studies in the
assessment of risk of bias and we will describe in the Discussion
section its impact on the findings of the review. We will perform
sensitivity analyses to assess how sensitive results are to changes in
the assumptions made in the ‘available case analysis.’
Assessment of heterogeneity
We will investigate meta-analysis results for clinical and statistical
heterogeneity.
We will check for heterogeneity by considering the following fac-
tors:
1. The clinical or methodological characteristics of the studies.
2. The results of the I² statistic for the quantification of the hetero-
geneity. The I² statistic describes the percentage of total variation
across studies that is due to heterogeneity rather than to chance
(Higgins 2003). We will judge the importance of the observed
value of I² depending on the magnitude and direction of effects
and the strength of evidence for heterogeneity (moderate to high
heterogeneity will be defined as I² of 50% or more).
If we find substantial heterogeneity, we will not pool the data,
but will attempt to explain the observed differences by examin-
ing individual study characteristics and by performing subgroup
analyses.
Assessment of reporting biases
In addition to the evaluation of reporting bias as described in the
’Assessment of risk of bias’ section, we will investigate reporting
biases (such as publication bias) using funnel plots, provided there
are 10 or more studies in the meta-analysis. We will assess fun-
nel plot asymmetry visually, and use formal tests for funnel plot
asymmetry. For continuous outcomeswewill use the test proposed
by Egger 1997, and for dichotomous outcomes we will use the
test proposed by Harbord 2006. If we detect asymmetry in any
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of these tests or if a visual assessment suggests it, we will perform
exploratory analyses to investigate it.
Data synthesis
We will carry out statistical analysis using the Review Manager 5
software (RevMan 2012). We will use a fixed-effect meta analysis
for combining datawhere it is reasonable to assume that studies are
estimating the same underlying treatment effect, i.e. where trials
are examining the same intervention, and we judge the outcome
definitions, study population and methods to be sufficiently sim-
ilar between studies. If there is clinical heterogeneity (regarding
interventions, study populations, methods and outcome defini-
tions) we will not pool the results. We will descriptively summarise
studies for which pooling of results is not possible. We will use the
fixed-effect model if I² is 50% or less. If I² is greater than 50% we
will use a random-effects model. We will present the results as the
average treatment effect with 95% confidence intervals, and the
estimate of I². We will set out the main findings of the review in a
’Summary of findings’ table prepared using the GRADE approach
usingGRADEprofiler software (Guyatt 2008).Wewill list all out-
comes for each comparison with estimates of relative effects along
with the number of participants and studies contributing data for
those outcomes. For each individual outcome, we will assess the
quality of the evidence using the GRADE approach, which in-
volves consideration of within-study risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias. We will rate the quality of
the body of evidence for each key outcomes as ’high’, ’moderate’,
’low’ or ’very low’.
Subgroup analysis and investigation of heterogeneity
We will undertake subgroup analysis, grouping the trials by radi-
ation dose (< 60 Gy versus ≥ 60 Gy). The usual radiation dose
in Ewing’s sarcoma in 40 to 60 Gy. Higher radiation doses are
associated with increased risk of adverse events, including second
malignancies, and lower doses are associated with suboptimal re-
sponse (Kuttesch 1996).
We will assess subgroup differences by interaction tests available
within RevMan. We will report the results of subgroup analyses
quoting the Chi² statistic and P value, and the interaction test I²
value.
Sensitivity analysis
Besides the sensitivity analyses mentioned earlier in this protocol,
we will conduct a repeat of the primary meta-analysis, excluding
studies at high risk or uncertain risk of bias. In this sensitivity
analysis, we will only include studies that have a low risk of bias
in all key domains for the estimates of treatment effect.
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A P P E N D I C E S
Appendix 1. Search strategy for Cochrane Central Register of Controlled Trials (CENTRAL)
1. ForEwing’s sarcoma the following text words will be used:
ewingOR ewingsOR ewing*OR ewing sarcomaOR ewing’s sarcomaORprimitive neuroepithelial tumorORprimitive neuroepithelial
tumors OR primitive neuroectodermal tumor OR primitive neuroectodermal tumors OR primitive neuroepithelial neoplasm OR
primitive neuroepithelial neoplasms OR primitive neuroectodermal neoplasms OR primitive neuroectodermal neoplasm OR PNET
OR PNETs OR sarcoma, soft tissue OR sarcomas, soft tissue OR soft tissue sarcoma OR soft tissue sarcomas OR “askin tumor” OR
“askin tumors” OR “askin tumour” OR “askin tumours” OR “askin tumor*” OR “askin tumour*”
2. For Radiotherapy the following text words will be used:
Radiotherapy OR radiation OR radiation therapy OR irradiation OR irradiat* OR radiation injuries OR injuries, radiation OR injury,
radiation OR radiation injury OR radiation syndrome OR radiation syndromes OR syndrome radiation OR radiation sickness OR
radiation sicknesses OR sickness radiation OR radiation* OR irradiation OR radiations
3. For Surgery the following text words will be used:
surgery OR surger* OR surgeri* OR surgical OR surgical* OR operation OR operat* OR operate OR operative procedure
Final search
1 AND (2 OR 3)
[*=zero or more characters]
The search will be performed in title, abstract or keywords
Appendix 2. Search strategy for PubMed
1. For Ewing’s sarcoma the following MeSH headings and text words will be used:
ewing[tiab] OR ewings[tiab] OR ewing*[tiab] OR ewing sarcoma[tiab] OR ewing’s sarcoma OR “primitive neuroepithelial tumor” OR
“primitive neuroepithelial tumors” OR “primitive neuroectodermal tumor” OR “primitive neuroectodermal tumors” OR “primitive
neuroepithelial neoplasm” OR “primitive neuroepithelial neoplasms” OR “primitive neuroectodermal neoplasms” OR “primitive neu-
roectodermal neoplasm” OR “PNET” OR “PNETs” OR (“askin tumor” OR “askin tumors” OR “askin tumour” OR “askin tumours”
OR “askin tumor*” OR “askin tumour*”)
2. ForRadiotherapy the following MeSH headings and text words will be used:
Radiotherapy OR radiation OR radiation* OR radiations OR radiation therapy OR irradiation OR irradiat* OR radiation injuries OR
injuries, radiation OR injury, radiation OR radiation injury OR radiation syndrome OR radiation syndromes OR syndrome radiation
OR radiation sickness OR radiation sicknesses OR sickness radiation
3. For Surgery the following MeSH headings and text words will be used:
surgery OR surger* OR surgeri* OR surgical OR surgical* OR Surgical Procedures, Operative[MeSH] OR operation OR operat* OR
operate OR operative procedure
4. For RCTs and CCTs the following MeSH headings and text words will be used:
((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh])
OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) AND (humans[mh])
Final search
1 AND (2 OR 3) AND 4
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[pt = publication type; tiab = title, abstract; sh = subject heading; mh = MeSH term; *=zero or more characters; RCT = randomized
controlled trial; CCT = controlled clinical trial]
Appendix 3. Search strategy for EMBASE (OVID)
1. For Ewing’s sarcoma the following Emtree terms and text words will be used:
1. (ewing or ewings or ewing$).ti,ab.
2. exp Ewing sarcoma/
3. (ewing sarcoma or ewing’s sarcoma).mp.
4. (PNET or PNETs).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
5. (peripheral neuroectodermal tumor or peripheral neuroectodermal tumors).mp.
6. (primitive neuroectodermal tumor or primitive neuroectodermal tumors).mp.
7. (Primitive Neuroepithelial Tumor or Primitive Neuroepithelial Tumors).mp.
8. neuroectoderm tumor/ or neuroepithelioma/
9. (Primitive Neuroepithelial Neoplasm or Primitive Neuroepithelial Neoplasms).mp.
10. exp soft tissue sarcoma/
11. (soft tissue sarcoma or soft tissue sarcomas).mp.
12. (askin tumor or askin tumors or askin tumour or askin tumours or askin tumor$ or askin tumor$).mp.
13. or/1-12
2. For Radiotherapy the following Emtree terms and text words will be used:
1. Radiotherapy.mp. or exp radiotherapy/
2. exp radiation/ or radiation.mp.
3. (radiation* or radiations).mp.
4. radiation therapy.mp.
5. radiation injuries.mp. or exp radiation injury/
6. radiation injury.mp.
7. exp irradiation/
8. (irradiation or irradiat$).mp.
9. exp radiation sickness/
10. (radiation syndrome or radiation syndromes).mp.
11. (syndrome radiation or radiation sickness or radiation sicknesses or sickness radiation).mp.
12. or/1-11
3. For Surgery the following Emtree terms and text words will be used:
1. exp surgery/
2. (surgery or surger$ or surgeri$).mp.
3. (surgical or surgical$).mp.
4. surgical technique/
5. (surgical procedure or surgical procedures).mp.
6. (operate or operat$ or operative procedure).mp.
7. operation/
8. or/1-6
4. For RCTs and CCTs the following Emtree terms and text words will be used:
1. Randomized Controlled Trial/
2. Controlled Clinical Trial/
3. randomized.ti,ab.
4. placebo.ti,ab.
5. randomly.ti,ab.
6. trial.ti,ab.
7. groups.ti,ab.
8. drug therapy.sh.
9. or/1-8
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10. Human/
11. 9 and 10
Final search
1 AND (2 OR 3) AND 4
[mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword; sh = subject heading; ti,ab = title, abstract; / = Emtree term; $=zero or more characters ; RCT = randomized
controlled trial; CCT = controlled clinical trial]
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